Lerner, A Martin, Beqaj, Safedin H, Deeter, Robert G et al. · In vivo (Athens, Greece) · 2004
Researchers tested blood samples from 58 ME/CFS patients and 68 healthy controls for antibodies to Epstein-Barr virus (EBV), a common virus that causes mononucleosis. They found that about half of the ME/CFS patients (33 out of 58) had elevated levels of a specific type of antibody called IgM against EBV, while none of the healthy controls had this pattern. These antibody levels stayed elevated in ME/CFS patients for up to 3.5 years, suggesting this test might help identify a particular subgroup of ME/CFS patients.
This finding is significant because identifying subgroups within ME/CFS based on specific viral antibody patterns could lead to better diagnostic tools and more targeted treatment approaches. If validated, an EBV VCA IgM test could help clinicians distinguish between different ME/CFS patient populations and potentially guide personalized management strategies.
This study does not prove that EBV directly causes ME/CFS in these patients—elevated antibodies indicate past or ongoing viral exposure, not necessarily active infection or causation. It also does not establish whether this antibody pattern is unique to CFS or whether treating any underlying viral reactivation would improve patient outcomes. The cross-sectional design means we cannot determine whether the antibodies appear before illness onset or develop as a consequence of illness.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →